Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02088112 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 3 | Apr 4, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02166242 |
| Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers |
| completed |
| Phase 1 |
| 40 |
| Hunan Province Tumor HospitalOTHER |
| 1 |
| Mar 16, 2022 |
| clinicaltrials |
| NCT01061840 | Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer | completed | Phase 1 | 100 | Gradalis, Inc.INDUSTRY | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03773380 | Breathe Anew for Lung Cancer Survivorship(BA) | completed | Phase 1 | 50 | St. Joseph's Healthcare HamiltonOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05226728 | Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer | completed | Phase 1 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | completed | Phase 1 / Phase 2 | 176 | Incyte CorporationINDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02403193 | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(AdenONCO) | completed | Phase 1 | 92 | Palobiofarma SLINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03514719 | PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)(PINNACLE) | completed | Phase 1 | 24 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT02938624 | Anti PD-1 Neo-adjuvant Treatment for NSCLC(MK3475-223) | completed | Phase 1 | 28 | Jair Bar, M.D., Ph.D.OTHER_GOV | 1 | Dec 14, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer(ENCORE110) | completed | Phase 1 | 14 | Syndax PharmaceuticalsINDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01757288 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | completed | Phase 1 / Phase 2 | 98 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01911507 | INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 35 | University of California, DavisOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT01586624 | A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) | completed | Phase 1 | 61 | Cancer Research UKOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT01449461 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | completed | Phase 1 / Phase 2 | 137 | Ariad PharmaceuticalsINDUSTRY | 0 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00857025 | Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT03086239 | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | completed | Phase 1 | 29 | AbbVieINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02964689 | Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | completed | Phase 1 | 18 | Swiss Cancer InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT02197247 | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT02429843 | A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | completed | Phase 1 | 16 | University of Alabama at BirminghamOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT01076231 | Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery | completed | Phase 1 / Phase 2 | 34 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01199068 | CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03380871 | A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | completed | Phase 1 | 38 | BioNTech US Inc.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 4, 2022source: clinicaltrials